Skip to content

Pain Management After Shoulder Arthroplasty

Multimodal Postoperative Pain Management Following Shoulder Arthroplasty

Status
UNKNOWN
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04872270
Enrollment
160
Registered
2021-05-04
Start date
2021-04-15
Completion date
2022-04-15
Last updated
2021-05-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Caffeine, Pain, Joint

Brief summary

Pain control is a critical after many surgical procedures. It is well known that orthopaedic surgeries are among the most painful procedures, with total joint arthroplasty being a clear example of this situation. Current trends in pain management are morphing and multimodal opioid sparing protocols are now being evaluated and implemented, with results showing a decrease in the amount of opioids being prescribed. Despite all efforts, most patients experience pain and, in order to control it, multiple medications have been tried with variable results. The most commonly prescribed medications are opioids, but side effects associated with their use as well as their addictive potential are making them a less desirable option for patients. Currently there is a trend towards diminishing opioids consumption and prescribing alternative pain control regimens.Caffeine is a well known molecule that when associated with non-steroidal anti-inflammatory drugs (NSAIDS) potentiates their analgesic effect and decreases the amount of doses required to control pain. Little is known about the effect of caffeine over pain relief in patients undergoing total joint arthroplasty, but preliminary results in other fields make us believe it could have a potential benefit for patients undergoing total joint arthroplasty.

Interventions

PROCEDURETotal Shoulder Arthroplasty

Participant will have total shoulder replacement

2 week supply of 1000 mg caffeine given postoperatively as part of the pain regimen

DRUGPercocet 10Mg-325Mg Tablet

given postoperatively as standard post-op pain management

DRUGZofran 4Mg Tablet

given postoperatively as standard post-op management

Sponsors

Rothman Institute Orthopaedics
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
55 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Adult patients who undergo primary Total Shoulder Arthroplasty or Reverse Total Shoulder Arthroplasty * Patient willing and able to complete postoperative surveys * Post-Menopausal Women and Men over the age of 55

Exclusion criteria

* Patients reporting caffeine consumption in excess of 300mg daily * Patient has known history of opioid addiction, has taken opioids preoperatively, or other forms of substance abuse. * Patient has history of cardiac diseases that might be aggravated by the use of caffeine, as diagnosed by a cardiologist or demonstrated by an abnormal EKG. * Patient has a known allergy to aspirin or caffeine. * Patient has history of cancer, neuropathic pain, or nerve degenerative disease that would affect patient reported outcomes including pain. * Patient has history of anxiety disorder * Patients with known sleep disturbances that would otherwise be affected by caffeine * Patients undergoing revision surgery * Patients who require alternate DVT prophylaxis other than ASA. * Patients undergoing inpatient arthroplasty * Workman's comp patient or patient has current litigation pending

Design outcomes

Primary

MeasureTime frameDescription
postoperative shoulder function24 weeksThis will be measured using the Simple Shoulder Test (SST) which consist of 12 questions
Postoperative shoulder function24 weeksThis will be measured using the American Shoulder and Elbow Surgeon Survey (ASES)
Postoperative Pain15 daysThis will be measured using the Visual Analog Scale for Pain (VAS) survey

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026